Advanced Helical Design. Unmatched SFA Outcomes.

**LIFEStent® Vascular Stent Systems**

**LIFEStent® XL Vascular Stent System**

<table>
<thead>
<tr>
<th>Deployment System</th>
<th>Catheter Length (cm)</th>
<th>Stent Diameter (mm)</th>
<th>Product code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX060100DC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX060100EC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX060120DC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX060120EC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX060140DC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX060140EC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX060160DC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX060160EC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX060180DC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX060180EC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX060200DC</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX060200EC</td>
</tr>
</tbody>
</table>

**LIFEStent® Solo® Vascular Stent System**

<table>
<thead>
<tr>
<th>Deployment System</th>
<th>Catheter Length (cm)</th>
<th>Stent Diameter (mm)</th>
<th>Product code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX062001C</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX062002C</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX062003C</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX062004C</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>6</td>
<td>EX062005C</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>7</td>
<td>EX062006C</td>
</tr>
</tbody>
</table>

**Contraindications:**

- Allergic/anaphylactoid reaction
- Amputation
- Aneurysm
- Arterial occlusion/thrombus
- By-pass Surgery
- Embolization
- Hemorrhage/bleeding
- Pseudoaneurysm
- Renal failure
- Restenosis
- Stent Fracture
- Stent Migration

**Potential Adverse Events:**

Potential adverse events which may be associated with the use of a stent in the SFA and proximal popliteal arteries include, but are not limited to:

- Myocardial ischemia
- Myocardial infarction
- Pericardial effusion
- Pulmonary embolism
- Renal failure
- Restenosis
- Thrombosis
- Venous thromboembolism
- Vascular complications

**Warnings:**

- The use of this device is limited to symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and proximal popliteal artery.
- Patients with a target lesion with a large amount of adjacent acute or subacute thrombus.
- Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system.
- Patients who cannot receive recommended antiplatelet and/or anti-coagulation therapy.

**Prescriptive Information:**

Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events and Operator’s Instructions.

**Bard**

**Vascular Stent Systems**

- **LIFEStent®**
- **7 200**
- **6 200**
- **170**
- **150**
- **120**
- **100**
- **80**
- **60**
- **40**
- **30**
- **20**
- **10**

**For all product codes: 0.035” Guidewire, 6F Catheter System.**

**NOT FOR SALE OR DISTRIBUTION IN THE U.S.**
TRIAL OVERVIEW

- 206 patients enrolled: 72 in PTA group, 134 in PTA and LifeStent® Vascular Stent group
- 24 study sites in United States and Europe
- Symptomatic De Novo or Restenosed Lesions
- Average stented length of 99 mm

TRUE HELICAL

- Engineered for Bending, Compression, Torsion
- Dynamic Vessel Conformability

- Improved Lesion Coverage With a Single Stent up to 200 mm

LIFEStENT®
Vascular Stent System

FDA APPROVED

- SFA and Proximal Popliteal Artery
- Vessel Diameters of 4.0 - 6.5 mm

RESILIENT
A prospective, randomized, controlled, multi-center study comparing LifeSTENT® Vascular Stent vs. Angioplasty alone in lesions of the SFA and/or proximal popliteal artery.

FREEDOM FROM TLR
The low fracture rate suggests the flexible helical design may afford some degree of fracture resistance.

200 mm

PRIMARY PATENCY RATE

- 81.3% p<0.0001
- 85.3% p<0.0001

STENT FRACTURE RATE

- 4.1%

200 mm

TRIAL OVERVIEW

- 206 patients enrolled: 72 in PTA group, 134 in PTA and LifeSTENT® Vascular Stent group
- 24 study sites in United States and Europe
- Symptomatic De Novo or Restenosed Lesions
- Average stented length of 99 mm